Q-omics provides the consensus-scored LYZL6 profile across patient tissues and cancer cell-line models. LYZL6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LYZL6 is differentially expressed in 3, with the highest sampling consensus in BLCA. Additionally, LYZL6 RNA expression shows 6,409 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, BLCA, and STAD as cancer lineages where LYZL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYZL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYZL6 survival associations across molecular data types. LYZL6 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYZL6 RNA expression–survival associations across cancer types. High LYZL6 expression shows unfavorable associations in UCEC, LGG, READ, ESCA, COAD and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UCEC as the clearest survival context for LYZL6 RNA expression.
This table summarizes LYZL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LYZL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYZL6 shows higher tumor expression in BLCA, HNSC and LIHC. The BLCA box plot shows higher LYZL6 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p = .017).
This table shows molecular features associated with LYZL6 in patient tissues and cancer cell lines. In patient samples, LYZL6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LYZL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
